ketoconazole and roflumilast

ketoconazole has been researched along with roflumilast in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Balliano, TL; Barbosa, G; Carvalho, VF; da Silva, BA; de Souza, ET; Lima, LM; Martins, IRR; Martins, MA; Medeiros, MM; Moraes Junior, MO; Nunes, IKDC; Silva, PMR; Silva, SWD	1
Hermann, R; Herzog, R; Huennemeyer, A; Lahu, G; McCracken, N; von Richter, O; Zech, K	1

Trials

1 trial(s) available for ketoconazole and roflumilast

Article	Year
Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide. Journal of clinical pharmacology, 2008, Volume: 48, Issue:11 Topics: Adult; Aminopyridines; Antifungal Agents; Benzamides; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Female; Humans; Ketoconazole; Male; Phosphodiesterase 4 Inhibitors; Young Adult	2008

Other Studies

1 other study(ies) available for ketoconazole and roflumilast

Article	Year
Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies. European journal of medicinal chemistry, 2020, Oct-15, Volume: 204 Topics: Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Design; Enzyme Inhibitors; Humans; Hydrazones; Hypersensitivity; Lung; Male; Mice	2020

Article

Year

Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.

European journal of medicinal chemistry, 2020, Oct-15, Volume: 204

Topics: Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Design; Enzyme Inhibitors; Humans; Hydrazones; Hypersensitivity; Lung; Male; Mice

2020